Biomedical literature, made navigable
Discover articles through diseases, drugs, treatments, interventions, clinical instruments, institutions and funders extracted from the BMJ open corpus.
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentionsChoose an entity to see the articles in which it was identified.
…of IT PH-762 in cutaneous squamous cell carcinoma, melanoma, or Merkel cell carcinoma, to determine the pharmacokinetic profile of PH-762 after IT in…
…rmed on a subset of patients (n=>10), including the addition of BAY2965501, demonstrated synergistic elevation in IFNγ and IL2 production …
…Background Lung cancer is the most common and deadly type of malignant tumor worldwide…
…ent for advanced biliary tract cancer (BTC) has been updated to immune checkpoint inhibitors combined with chemotherapy. However, immuno-chemotherapy for BT…
…llow for an in-depth understanding of the synergistic effect of mANK-101 with HDAC inhibition.Conclusions Collectively, these findings p…
…T cells in the tumor microenvironment driven by the therapeutic cancer vaccine and the adenosine inhibitors that block the inhibitory …
… cancer (NSCLC) where immunotherapy is standard of care.Methods Daraxonrasib, a RAS(ON) multi-selective inhibitor, and elironrasib, a RAS(ON…
…reatment resulted in 70-95% tumor growth inhibition.Conclusions IMM-2510 is an anti-PD-L1xVEGF bispecific antibody designed to have immu…
…d with PD-1/PD-L1 therapies between years 2013 and 2024, at the University of Michigan. 38 male patients were subdivided based upon melanoma subtype, …
…Conclusions Our research aims to understand how SOX10-deficient melanoma alters the composition and function of the tumor immune microen…
…Background Pancreatic cancer is complicated by many factors, including the unique tumor micr…
…in only marginal tumor control (<40% TGI) without achieving CR. HM16390 elicited an improved, yet still insufficient, anti-tumor activi…